All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Lung cancer is the leading cause of cancer mortality \[[@pone.0177875.ref001]\]. Most lung cancers are caused by tobacco smoking \[[@pone.0177875.ref002]\], although associations have also been reported with a range of inflammatory and metabolic conditions. Observational studies have indicated an inverse relationship for both body mass index (BMI) \[[@pone.0177875.ref003]--[@pone.0177875.ref007]\] and lipid levels \[[@pone.0177875.ref008],[@pone.0177875.ref009]\], as well as a positive correlation with dietary glycemic index \[[@pone.0177875.ref010]\] and insulin levels \[[@pone.0177875.ref011]\], with lung cancer risk. However, given the strong effect of tobacco smoking on lung cancer risk, and the well described association between tobacco consumption and alterations in body weight \[[@pone.0177875.ref012]--[@pone.0177875.ref014]\], traditional observational studies are unlikely to fully account for the confounding effect of tobacco exposure when describing the relationship between lung cancer and obesity or metabolic conditions.

Mendelian randomization (MR) is an analytical approach based on genetic markers of an exposure (i.e. an instrumental variable) that is less sensitive to reverse causation and confounding than traditional regression analyses in observational studies \[[@pone.0177875.ref015]\]. Inherited gene variants associated with the risk factors of interest should act as unconfounded markers of those risk factors, assuming an absence of pleiotropy \[[@pone.0177875.ref016]\]. In this instance, an association between the genetic variant and the outcome implies that the risk factor of interest may have a causal effect on the outcome \[[@pone.0177875.ref017]\]. Previous MR analyses on lung cancer risk showed that a genetic score for increased BMI raised the risk for lung cancer, especially for squamous cell carcinoma and small cell lung cancer \[[@pone.0177875.ref018],[@pone.0177875.ref019]\]. These results are in contradiction to observational findings, confirming the utility of MR analyses for this exposure.

The goal of the current study was to use genetic variations associated with a range of metabolic factors, including obesity, body shape, dyslipidemia and hyperglycemia, to further investigate the causal relationship between these metabolic exposures and lung cancer. The method applied in this study is called two-sample MR, which combines summary statistics on genetic variant-exposure and genetic variant-outcome associations from different samples \[[@pone.0177875.ref020],[@pone.0177875.ref021]\]. Furthermore, we sought to confirm that the genetic control of these metabolic phenotypes did not influence cigarette smoking behavior.

Methods {#sec005}
=======

Genetic instruments for obesity and metabolic parameters {#sec006}
--------------------------------------------------------

Genetic instruments for potential risk factors were independent (linkage disequilibrium (LD) R^2^ \< 0.01 in European 1000 Genomes Phase3 samples \[[@pone.0177875.ref022]\]) single nucleotide polymorphisms (SNPs) that were associated with the trait of interest in the most recent genome-wide association study (GWAS) (P\<5x10^-8^) on European ancestry samples. Results from the Genetic Investigation of ANthropometric Traits (GIANT) consortium were used to identify genetic proxies for body mass index (BMI) \[[@pone.0177875.ref023]\], and waist to hip ratio \[[@pone.0177875.ref024]\]. High-density and low-density lipoprotein cholesterol (HDL and LDL), total cholesterol and triglycerides were selected as lipid profile components. Genetic loci influencing bloodstream levels of these lipids were identified from GWA data provided by the Global Lipids Genetic Consortium (GLGC) \[[@pone.0177875.ref025]\]. Additionally, genetic instruments of low frequency were also identified for HDL, LDL cholesterol and triglycerides \[[@pone.0177875.ref026]\]. Finally, hyperglycemia and hyperinsulinemia parameters were reported within the Meta-Analysis of Glucose and Insulin related traits Consortium (MAGIC) at fasting levels and during an oral glucose tolerance test (OGTT). Genetic instruments were identified for plasma levels of fasting glucose, fasting insulin and 2-hour post-challenge glucose \[[@pone.0177875.ref027]\]. For these metabolic parameters, in order to reduce potential pleiotropic effect from BMI, SNPs that were not associated with the phenotype once adjusted for BMI (P\>0.05) were excluded from our analyses. For each identified SNP, the reported effect was for the increasing trait allele expressed in standard deviations (SD) of the trait per-allele (β~GP~) along with the standard error (SE~GP~). For the studies in which the genetic effects were not originally reported in SDs of the trait, they were recalibrated according to the mean SD, weighted for sample size, reported across different case-control samples. SNPs with ambiguous strand codification (A/T or C/G) were replaced by SNPs in tight genetic linkage (R^2^\>0.8) using the *proxysnps* R package (European populations) (R Project) or removed from the analyses. Details on i) the number of SNPs identified for each potential risk trait, ii) the mean and SD of the traits in the discovery GWAS, and iii) the proportion of trait variance explained by the genetic proxies are presented in [Table 1](#pone.0177875.t001){ref-type="table"}.

10.1371/journal.pone.0177875.t001

###### Number of identified instrumental SNPs for metabolic factors, phenotype distribution in the discovery sample, and proportion of phenotype variance explained by the instruments.

SD: standard deviation.

![](pone.0177875.t001){#pone.0177875.t001g}

  Phenotype                     N SNP   Mean ± SD          Units     Variance explained (%)   Consortium   Publication for instruments
  ----------------------------- ------- ------------------ --------- ------------------------ ------------ ---------------------------------------------------
  Body mass index               73      27.0 ± 4.6         kg/m^2^   2.7                      GIANT        Locke et al 2015 \[[@pone.0177875.ref023]\]
  Waist to hip ratio            32      1.1 ± 0.1          cm/cm     1.4                      GIANT        Shungin et al 2015 \[[@pone.0177875.ref024]\]
  High density cholesterol      63      53.3 ± 15.5        mg/dl     13.7                     GLGC         Willer et al 2013 \[[@pone.0177875.ref025]\]
  Low density cholesterol       50      133.6 ± 38.0       mg/dl     14.6                     GLGC         Willer et al 2013 \[[@pone.0177875.ref025]\]
  Total cholesterol             67      213.28 ± 42.6      mg/dl     15.0                     GLGC         Willer et al 2013 \[[@pone.0177875.ref025]\]
  Triglycerides                 39      140.85 ± 87.8      mg/dl     11.7                     GLGC         Willer et al 2013 \[[@pone.0177875.ref025]\]
  HDL rare variants             11      1.4 ± 0.4          mmol/l    4.1                      \-           Helgadottir et al 2016 \[[@pone.0177875.ref026]\]
  Non-HDL rare variants         11      4.0 ± 1.2          mmol/l    4.1                      \-           Helgadottir et al 2016 \[[@pone.0177875.ref026]\]
  Triglycerides rare variants   7       1.3 ± (0.8--2.2)   mmol/l    2.4                      \-           Helgadottir et al 2016 \[[@pone.0177875.ref026]\]
  Fasting glucose               25      5.2 ± 0.8          mmol/l    4.8                      MAGIC        Scott et al 2012 \[[@pone.0177875.ref027]\]
  Fasting insulin               11      56.9 ± 44.4        pmol/l    1.2                      MAGIC        Scott et al 2012 \[[@pone.0177875.ref027]\]
  2h post-challenge glucose     6       5.6 ± 1.7          mmol/l    1.7                      MAGIC        Scott et al 2012 \[[@pone.0177875.ref027]\]

Lung cancer association results {#sec007}
-------------------------------

GWAS results on overall lung cancer risk and by histology type were obtained from the recently completed meta-analyses \[[@pone.0177875.ref028]\] comprising the previous TRICL-ILCCO lung cancer GWAS (11,177 lung cancer cases and 40,396 controls) \[[@pone.0177875.ref029]\] and an additional 18,089 lung cancer samples and 16,054 controls genotyped using the Illumina Infinium OncoArray-500K BeadChip (Illumina Inc. San Diego, CA). The overall sample size was 29,266 lung cancer cases and 56,450 controls. GWAS analyses were stratified by histology, including 11,273 adenocarcinomas, 7,426 squamous cell carcinomas and 2,664 small cell lung cancers. Additionally, analyses were performed stratified by smoking status defined as ever smokers (current and former smokers; 23,223 cases and 16,964 controls) and never smokers (2,355 cases and 7,504 controls). SNPs with imputation quality score (R^2^) less than 0.7 were removed from the datasets. For all SNPs used as instruments in this report, SNP to phenotype effect (β~GP~) and SNP to disease effect (β~GD~) for each lung cancer subgroup can be observed in [S1 Table](#pone.0177875.s022){ref-type="supplementary-material"}.

Power assessment {#sec008}
----------------

Power calculations on MR analyses were performed according to Burgess \[[@pone.0177875.ref030]\], given the number of cases and controls of the lung cancer subgroups, for five genetic instruments accounting for different proportion of explained variance (1%, 2.5%, 5%, 10% and 15%) within the range of our genetic instrument sets (see [Table 1](#pone.0177875.t001){ref-type="table"}). Power calculations are presented in [S1 Fig](#pone.0177875.s001){ref-type="supplementary-material"}.

Mendelian randomization analyses on lung cancer {#sec009}
-----------------------------------------------

The causal risk effects of metabolic factors on lung cancer overall, as well as by histology and other subgroups were estimated using a likelihood-based approach, which is considered the most accurate method to estimate causal effects when there is a continuous log-linear association between risk factor and disease risk \[[@pone.0177875.ref020]\]. The resulting odds ratio (OR) and 95% confidence interval (CI) provide an estimate of relative risk caused by each SD increase in the exposure. We investigated the heterogeneity of causal effects by histology and by smoking status, estimating the *I*^*2*^ statistic assuming a fixed-effect model using the *meta* R package (R project). We also provide OR estimates using the complementary weighted median method wherein the causal effect estimate is weighted towards the median of the distribution of instrumental SNPs \[[@pone.0177875.ref031]\]. This approach is less sensitive to individual instrumental SNPs behaving as outliers. Furthermore, because OR estimates can be confounded if the instrumental genetic variants are also associated with other causal risk factors, i.e. through directional pleiotropy, we also performed MR-Egger \[[@pone.0177875.ref032]\]. This approach involves a weighted linear regression of the SNP to disease effects (β~GD~) on the SNP to phenotype effects (β~GP~), and provides a direct estimate of any directional pleiotropy under the assumption that pleiotropic biases affecting the overall MR risk estimates are acting in the same direction \[[@pone.0177875.ref033]\]. Additionally, MR-Egger regression is able to identify SNPs behaving as genetic outliers, providing Bonferroni corrected P-values. We also provide a funnel plot of the fold risk increase (exp(β~GD~/β~GP~)) vs. the instrumental strength of each SNP (β~GP~/SE~GD~^2^) to allow visual assessment of asymmetry of instrumental causal estimates. These plots were generated using the *ggplot2* R package (R Project).

Assessment of association between the genetic instruments and other phenotypes {#sec010}
------------------------------------------------------------------------------

To evaluate whether MR lung cancer risk estimates could be generated by other phenotypes than the instrumented ones, the association of genetic instruments with other phenotypes was assessed. The effects of our genetic instruments on cigarette smoking was evaluated using a novel online platform for Mendelian randomization based on summary genetic association data from GWAS (MR-Base; <http://www.mrbase.org/>) \[[@pone.0177875.ref034]\]. Genetic effects on cigarette smoking (cigarettes per day) were obtained from the Tobacco and Genetics (TAG) consortium \[[@pone.0177875.ref035]\]. TAG data were generated from 16 independent studies which included 38,181 smokers with information on number of smoked cigarettes per day. We also assessed the association of dyslipidemia and hyperglycemia genetic instruments with BMI using data from the GIANT consortium \[[@pone.0177875.ref023]\].

Results {#sec011}
=======

Obesity and body shape parameters {#sec012}
---------------------------------

Based on 72 SNPs used as genetic instruments for BMI, we estimated an overall OR (per SD increase in BMI (4.6 kg/m^2^)) of 1.07 (95%CI = 0.96--1.20) for lung cancer risk ([Fig 1](#pone.0177875.g001){ref-type="fig"}). However, stratified analyses by histology subtypes revealed heterogeneity in the causal effect estimates (*P*~*heterogeneity*~ *= 4*.*3x10*^*-3*^), with no effect on adenocarcinoma (OR \[95%CI\] = 0.93 \[0.79--1.08\]), but an increased risk for squamous cell carcinoma (OR \[95%CI\] = 1.20 \[1.01--1.43\]) and small cell lung cancer (OR \[95%CI\] = 1.52 \[1.15--2.00\]) ([Fig 2](#pone.0177875.g002){ref-type="fig"}). Analyses stratified by smoking status showed a null effect of BMI in never smokers (OR \[95%CI\] = 0.83 \[0.60--1.16\]) and in ever smokers (OR \[95%CI\] = 1.12 \[0.97--1.29\]) (*P*~*heterogeneity*~ = 0.10) ([Fig 2](#pone.0177875.g002){ref-type="fig"}). Weighted median MR approach provided similar risk estimates for the different lung cancer types ([S2 Table](#pone.0177875.s023){ref-type="supplementary-material"}). The MR-Egger intercept test revealed the presence of bias on the initial risk estimation on lung cancer overall and in ever-smokers ([S3 Table](#pone.0177875.s024){ref-type="supplementary-material"}), with MR-Egger risk estimates indicating no effect of BMI on lung cancer overall. Potential asymmetry of the SNP' risk estimates reflected the presence of directional pleiotropy for lung cancer overall ([Fig 3A](#pone.0177875.g003){ref-type="fig"}). Funnel plots for the other histological types can be observed in the funnel plots included in [Fig 3B--3F](#pone.0177875.g003){ref-type="fig"}. Regarding waist-to-hip ratio, there was no evidence of causal effect on lung cancer overall (OR \[95%CI\] = 1.04 \[0.87--1.25\]) ([Fig 1](#pone.0177875.g001){ref-type="fig"}) or histology subgroups ([S2 Fig](#pone.0177875.s002){ref-type="supplementary-material"}). Sensitivity analyses did not detect any effect biasing the initial risk estimates ([S2](#pone.0177875.s023){ref-type="supplementary-material"} and [S3](#pone.0177875.s024){ref-type="supplementary-material"} Tables). Funnel plots can be observed in [S3 Fig](#pone.0177875.s003){ref-type="supplementary-material"}.

![Forest plot of lung cancer overall risk for one standard deviation ([Table 1](#pone.0177875.t001){ref-type="table"}) increase in each phenotype provided by the MR likelihood-based approach.\
CI: Confidence interval. P: P value.](pone.0177875.g001){#pone.0177875.g001}

![Forest plot of lung cancer risk for each SD increase in BMI (approximately 4.6 kg/m^2^) observed in the likelihood-based MR approach.\
95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.](pone.0177875.g002){#pone.0177875.g002}

![Funnel plots for the distribution of risk estimates of BMI instrumental SNPs along with MR causal effect lung cancer subtypes.\
OR: Odds ratio; Int: Intercept; P: P value.](pone.0177875.g003){#pone.0177875.g003}

Blood lipid levels {#sec013}
------------------

There was no consistent evidence of a causal effect of HDL on lung cancer overall (OR \[95%CI\] = 1.01 \[0.94--1.07\] for instrumental common SNPs, and OR \[95%CI\] = 1.07 \[0.95--1.21\] for instrumental rare SNPs) ([Fig 1](#pone.0177875.g001){ref-type="fig"}), nor any lung cancer subgroup ([S4](#pone.0177875.s004){ref-type="supplementary-material"}--[S7](#pone.0177875.s007){ref-type="supplementary-material"} Figs). Triglyceride levels did not indicate any effect on lung cancer overall; (OR \[95%CI\] = 0.98 \[0.91--1.06\] for instrumental common SNPs and OR \[95%CI\] = 0.87 \[0.70--1.08\] for instrumental rare SNPs) ([Fig 1](#pone.0177875.g001){ref-type="fig"}), or for lung cancer subtypes ([S8](#pone.0177875.s008){ref-type="supplementary-material"}--[S11](#pone.0177875.s011){ref-type="supplementary-material"} Figs). An inverse relationship was observed with overall lung cancer risk for each SD increase in LDL (approximately 38.0 mg/dl) (OR \[95%CI\] = 0.90 \[0.84--0.97\] for instrumental common SNPs ([Fig 1](#pone.0177875.g001){ref-type="fig"}), although stratified analyses did not provided a consistent inverse association among histology types (OR of 0.93 for adenocarcinoma (95%CI = 0.85--1.03), 0.88 for squamous cell carcinoma (95%CI = 0.79--0.98), and 0.96 for small cell lung cancer (95%CI = 0.81--1.14) ([Fig 4](#pone.0177875.g004){ref-type="fig"} and [S12 Fig](#pone.0177875.s012){ref-type="supplementary-material"} for funnel plots). Additionally, LDL instrumental rare SNPs did not provide evidence of association with lung cancer overall (OR \[95%CI\] = 1.09 \[0.93--1.27\]) ([Fig 1](#pone.0177875.g001){ref-type="fig"}) or subtypes ([S13](#pone.0177875.s013){ref-type="supplementary-material"} and [S14](#pone.0177875.s014){ref-type="supplementary-material"} Figs for funnel plots). Finally, total cholesterol showed a similar pattern of association with lung cancer overall and with subtypes that LDL common SNPs (OR of 0.94 for lung cancer overall (95%CI = 0.88--1.01), OR of 1.01 for adenocarcinoma (95%CI = 0.92--1.10), 0.89 for squamous cell carcinoma (95%CI = 0.80--1.00), and 0.93 for small cell lung cancer (95%CI = 0.79--1.10)) ([S15](#pone.0177875.s015){ref-type="supplementary-material"} and [S16](#pone.0177875.s016){ref-type="supplementary-material"} Figs for funnel plots).

![Forest plot of lung cancer risk for each SD increase in LDL (approximately 38.0 mg/dl) observed in the likelihood-based MR approach using the instrument set of common SNPs.\
95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.](pone.0177875.g004){#pone.0177875.g004}

Insulin resistance parameters {#sec014}
-----------------------------

Among glucose and insulin parameters, fasting insulin was associated with an increased risk in overall lung cancer (OR \[95%CI\] = 1.63 \[1.25--2.13\] per each SD increase \[44.4 pmol/l\]) ([Fig 1](#pone.0177875.g001){ref-type="fig"}). Stratified analyses provided consistent associations with all histology subtypes ([Fig 5](#pone.0177875.g005){ref-type="fig"}), with a risk increase of 1.60 for adenocarcinoma (95%CI = 1.12--2.31), 1.84 for squamous cell carcinoma (95%CI = 1.20--2.81), and 2.46 for small cell lung cancer (95%CI = 1.26--4.81). Stratified analyses by smoking status showed some heterogeneity in causal effects (*P*~*heterogeneity*~ *= 0*.*16)* ([Fig 5](#pone.0177875.g005){ref-type="fig"}), with a clear increased risk among ever smokers (OR \[95%CI\] = 1.86 \[1.33--2.60\]), but no association among never smokers (OR \[95%CI\] = 1.01 \[0.46--2.20\]). Sensitivity tests identified rs4865796 as an outlier SNP in the analyses for lung adenocarcinoma subtype and lung cancer overall in ever smokers. Removing this SNP, the analyses indicated slightly higher levels of risk associated with this genetic instrument (Funnel plots in [S17 Fig](#pone.0177875.s017){ref-type="supplementary-material"}).

![Forest plot of lung cancer risk for each SD increase in fasting insulin (approximately 44.4 pmol/L) observed in the likelihood-based MR approach.\
95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.](pone.0177875.g005){#pone.0177875.g005}

Fasting glucose showed little evidence for an association with overall lung cancer risk (OR per SD of 0.8 mmol/l = 1.10; 95%CI = 0.96--1.26) ([Fig 1](#pone.0177875.g001){ref-type="fig"}), nor for adenocarcinoma (OR \[95%CI\] = 1.03 \[0.85--1.24\] or small cell lung cancer (OR \[95%CI\] = 1.19 \[0.83--1.68\]), where a positive association with risk was seen for squamous cell carcinoma (OR \[95%CI\] = 1.32 \[1.06--1.65\]) ([S18](#pone.0177875.s018){ref-type="supplementary-material"} and [S19](#pone.0177875.s019){ref-type="supplementary-material"} Figs for funnel plots). Finally, 2-hour post-challenge glucose showed no evidence of causality for lung cancer overall (OR \[95%CI\] = 0.96 \[0.77--1.20\]) ([Fig 1](#pone.0177875.g001){ref-type="fig"}) or any lung cancer subgroup ([S20](#pone.0177875.s020){ref-type="supplementary-material"} and [S21](#pone.0177875.s021){ref-type="supplementary-material"} Figs for funnel plots).

Assessment of association between the genetic instruments and other phenotypes {#sec015}
------------------------------------------------------------------------------

Using MR-Base, we also evaluated the association between cigarette smoking for each genetic instrument associated with lung cancer risk, including BMI, LDL, and fasting insulin. Each SD increase in BMI increased cigarette consumption by 1.27 cigarettes (95%CI = 0.46:2.07; P = 2.1x10^-3^; MR likelihood-based approach), while the other metabolic genetic instruments were not associated with cigarette smoking (MR likelihood-based estimate per SD increase \[95%CI\] = -0.35 \[-0.92:0.22\] for LDL and 1.21 \[-0.67:3.08\] for fasting insulin). Additionally, each SD increase in LDL was inversely associated with BMI (-0.02 SD in BMI (95%CI = -0.04:-3.8x10^-3^; P = 0.02), while each SD increase in fasting was not associated with BMI (0.07 SD in BMI (95%CI = -0.01:0.15; P = 0.10)).

Discussion {#sec016}
==========

We have used existing data from large GWAS on metabolic factors to identify potentially causal risk factors of lung cancer that are amenable to intervention. Our results suggested that higher BMI is associated with an increase in risk of squamous and small cell carcinoma of the lung, and that this relation may be mediated by altered smoking behavior. Additionally, we found consistent evidence of a positive association between fasting insulin and overall lung cancer risk, as well as an inverse relationship between LDL levels and lung cancer risk.

Obesity and related metabolic factors are associated with risk of several cancers \[[@pone.0177875.ref036]\], but traditional observational studies are not reliable for assessing the association between metabolic factors and cancers strongly associated with smoking. The strength of the association between BMI and lung cancer subtypes found in this study, were weaker than those reported in previous MR analyses (45%-81% of risk increase) \[[@pone.0177875.ref018],[@pone.0177875.ref019]\]. These previous studies were based on smaller sample sizes (12,160 and 16,572 lung cancer cases, respectively), whereas our current study provides causal estimates from 29,266 lung cancer cases and 56,450 controls, including the samples of previous studies. Our analysis also detected a strong positive effect of each unit increase in BMI on number of cigarettes smoked per day, indicating that the associations with risk of squamous and small cell carcinoma lung cancer are caused by an influence of BMI on smoking behavior. Given that this association was derived from genetic data on BMI, and therefore not influenced by any inverse effect that tobacco consumption may have on BMI levels, it has important implications beyond this study on the smoking behavior and smoking prevention.

Our results lend further support to epidemiological studies showing an increased lung cancer risk for the effect of reduced lipid levels \[[@pone.0177875.ref009]\] and elevated circulating insulin \[[@pone.0177875.ref011]\]. Several studies have reported an inverse relationship between total cholesterol levels and cancer risk \[[@pone.0177875.ref037]\], which has been previously interpreted as an effect of preclinical cancer due to an increased uptake of cholesterol by tumor cells \[[@pone.0177875.ref009]\]. In contrast, our study suggests a potential relationship between cholesterol levels and lung cancer. However, cholesterol genetic instruments using common and rare SNPs did not provide homogeneous results. This could be explained by different observations: by the inverse relationship between the instrument set of common SNPs for cholesterol and BMI revealed by a sensitivity analysis using MR-Base, by a multiple testing effect, but also by the different proportion of exposure that genetic instruments represent (instrument sets of rare SNPs were weaker and had less power to detect potential causal associations). Further MR mediation analyses are needed in order to clarify the causal relationship between lipid levels and lung cancer accounting for the potential effect of BMI and smoking. Finally, the risk increase observed by fasting glucose and fasting insulin is unlikely to be driven by cigarette smoking or BMI, since the relevant instrumental sets are not associated with smoking or BMI. A potential causal relationship between increased insulin and cancer risk using genetic instruments has also been reported for endometrial cancer \[[@pone.0177875.ref038]\] and pancreatic cancer \[[@pone.0177875.ref039]\]. These results lend further support for an important role of the insulin-pathway in cancer aetiology \[[@pone.0177875.ref040]--[@pone.0177875.ref042]\].

One of the main caveats in Mendelian randomization studies is the potential violation of methodological assumptions, in particular the lack of directional pleiotropic effects biasing association estimates. In the current study we evaluated the extent to which pleiotropy may have affected our risk estimates using MR-Egger regression, as well as the MR-Base platform to directly assess the relation between genetic instruments and potential confounders.

In conclusion, using a two-sample Mendelian randomization approach, this study assessed a range of metabolic factors in relation to lung cancer risk. Our results revealed that genetic associations between BMI and lung cancer subtypes could be mediated by a positive relationship between BMI and cigarette consumption. Our results are also consistent with observational studies that indicate an inverse relationship between lipid levels and lung cancer risk, and an increasing risk caused by elevated fasting insulin levels.

Supporting information {#sec017}
======================

###### Power calculations for Mendelian randomization analyses on lung cancer using genetic instruments accounting for different proportion of phenotypic variance (15.0, 10.0, 5.0, 2.5, and 1.0%).
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Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase of waist-to-hip ratio observed in a likelihood-based MR approach.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)

###### 

Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of waist-to-hip ratio-instrumental SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in HDL observed in a likelihood-based MR approach using the instrument set of common SNPs.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in HDL observed in a likelihood-based MR approach using the instrument set of rare SNPs.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)
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Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of HDL instrumental common SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of HDL instrumental rare SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in triglycerides observed in a likelihood-based MR approach using the main instrument set of common SNPs.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in triglycerides observed in a likelihood-based MR approach using the instrument set of rare SNPs.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)
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Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of triglycerides instrumental common SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)
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Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of triglycerides instrumental rare SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)
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Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of LDL instrumental common SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in LDL observed in a likelihood-based MR approach using the instrument set of rare SNPs.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)

###### 

Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of LDL instrumental rare SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in total cholesterol observed in a likelihood-based MR approach.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)

###### 

Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of total cholesterol instrumental SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)
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Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of fasting insulin instrumental SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in fasting glucose observed in a likelihood-based MR approach.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)

###### 

Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of fasting glucose instrumental SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Forest plot of lung cancer risk for each SD increase in glucose 2h post-challenge observed in a likelihood-based MR approach.

95%CI: 95% Confidence Interval; P: P value. I^2^: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.

(PDF)

###### 

Click here for additional data file.

###### Funnel plots for the distribution of risk estimates of glucose 2h post-challenge instrumental SNPs along with MR causal effect lung cancer subtypes.

OR: Odds ratio; Int: Intercept; P: P value.

(PDF)

###### 

Click here for additional data file.

###### Association parameters of instrumental SNPs for the corresponding metabolic factor and for different lung cancer groups.

CHR: Chromosome. BP: Base pair. SE: Standard error. BMI: Body mass index. HDL: High-density lipoprotein, LDL: Low-density lipoprotein.

(PDF)

###### 

Click here for additional data file.

###### Risk increase on lung cancer phenotypes for each standard deviation increase in the phenotype provided by weighted median MR approach.

HDL: High-density lipoprotein, LDL: Low-density lipoprotein. Chol: Cholesterol. OR: Odds ratio. LCI: Lower confidence interval. UCI: Upper confidence interval. P: P value.

(PDF)

###### 

Click here for additional data file.

###### Overall pleiotropic effect assessment of causal estimates of potential risk factors on lung cancer phenotypes provided by MR-Egger test.

Int: Intercept. HDL: High-density lipoprotein, LDL: Low-density lipoprotein. Chol: Cholesterol. OR: Odds ratio. Est: Estimate. LCI: Lower confidence interval. UCI: Upper confidence interval. P: P value.

(PDF)

###### 

Click here for additional data file.
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